Elderly patient with comorbid pathology in the practice of a cardiologist
E.V. Ekusheva
Institution of Advanced Training of Federal Medical and Biological Agency, Moscow
An increase in life expectancy in a population and the aging of a population represent a global demographic phenomenon all over the world. This category of patients is distinguished, on the one hand, by the polymorbidity of pathological states with specific manifestations of each of them, mainly by the chronic course of existing diseases, and on the other hand, by the difficulty of diagnostics and selecting drug therapy. A high prevalence of cardiovascular disease and its frequent pathogenetic relationship with various comorbid diseases and conditions is a serious problem for any clinician, since he needs to take into account several components of therapy, which makes it difficult to control the effectiveness of the treatment, increases the likelihood of topical and systemic adverse events of drugs and also reduces adherence to therapy. Treatment of comorbid disorders requires careful compliance with the requirements of rational pharmacotherapy, high clinical professionalism and a wide range of knowledge of the physician in related specialties. Using the criteria of the American Geriatrics Society (Beers criteria) for patients over 65 years of age can help rationalize the pharmacotherapy of this category of patients in inpatient and outpatient visits.
Key words: comorbid pathology, polymorbidity, cardiovascular diseases, rational pharmacotherapy, polypragmasy.
For citation: Ekusheva E.V. Elderly patient with comorbid pathology in the practice of a cardiologist // RMJ. Medical Review. 2018. № 11. P. 26–29.
References
1. Евдокимова А.Г., Евдокимов В.В. Кардиоцеребральная дисфункция: факторы риска и возможности цитопротективной терапии // Эффективная фармакотерапия. Эффективная фармакотерапия. Кардиология и ангиология. 2013. Т. 1 (11). С. 6–10 [Yevdokimova A. G., Yevdokimov V.V. Kardiotserebral’naya disfunktsiya: faktory riska i vozmozhnosti tsitoprotektivnoy terapii // Effektivnaya farmakoterapiya. Effektivnaya farmakoterapiya. Kardiologiya i angiologiya. 2013. T. 1 (11). S. 6–10 (in Russian)].
2. Оганов Р.Г., Денисов И.Н., Симаненков В.Т. и др. Коморбидная патология в клинической практике. Клинические рекомендации // Кардиоваскулярная терапия и профилактика. 2017. Т. 16 (6). С. 5–56 [Oganov R.G., Denisov I.N., Simanenkov V.T. i dr. Komorbidnaya patologiya v klinicheskoy praktike. Klinicheskiye rekomendatsii// Kardiovaskulyarnaya terapiya i profilaktika. 2017. T. 16 (6). S. 5–56 (in Russian)].
3. Вёрткин А.Л., Румянцев М.А., Скотников А.С. Коморбидность // Клиническая медицина. 2012. № 10. С. 4–11 [Vortkin A.L., Rumyantsev M.A., Skotnikov A.S. Komorbidnost’ // Klinicheskaya meditsina. 2012. № 10. S. 4–11 (in Russian)].
4. Linn B.S., Linn M.W., Gurel L. Cumulative illness rating scale // J. Amer. Geriatr. Soc. 1968. Vol. 16. P. 622–626.
5. Miller M.D., Towers A. Manual of Guidelines for Scoring the Cumulative Illness Rating Scale for Geriatrics (CIRS-G). Pittsburg, Pa: University of Pittsburgh; 1991.
6. De Groot V. How to measure comorbidity: a critical review of available methods // J. Clin.Epidemiol. 2003. Vol. 56 (3). P. 221–229.
7. Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatmentof coronary artery disease: a workshop consensus statement // Am. Heart J. 1991. Vol. 121. P. 1244–1263.
8. Dzau V., Elliott M.A., Henry R.B. et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease) // Circulation. 2006. Vol. 114 (25). P. 2850–2870.
9. Chrysant S.G. A new paradigm in the treatment of the cardiovascular disease continuum: focus on prevention // Hippokratia. 2011. Vol. 15 (1). P. 7–11.
10. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults // J. Am. Geriatr. Soc. 2012. Vol. 60 (4). P. 616–631.
11. Сычев Д.А., Данилина К.С., Отделенов В.А. Клинико-фармакологические подходы к решению проблемы полипрагмазии у пожилых пациентов в условиях многопрофильного стационара // Клиническая фармакология и терапия. 2013. Т. 22 (2). С. 1–6 [Sychev D.A., Danilina K.S., Otdelenov V.A. Kliniko-farmakologicheskiye podkhody k resheniyu problemy polipragmazii u pozhilykh patsiyentov v usloviyakh mnogoprofil’nogo statsionara // Klinicheskaya farmakologiya i terapiya. 2013. T. 22 (2). S. 1–6 (in Russian)].
12. Дамулин И.В., Екушева Е.В. Деменция вследствие поражения мелких церебральных сосудов: патогенез, клиника, лечение // Неврология, нейропсихиатрия, психосоматика. 2014. № 4. С. 94–100 [Damulin I.V., Yekusheva Ye.V. Dementsiya vsledstviye porazheniya melkikh tserebral’nykh sosudov: patogenez, klinika, lecheniye // Nevrologiya, neyropsikhiatriya, psikhosomatika. 2014. № 4. S. 94–100 (in Russian)].
2. Оганов Р.Г., Денисов И.Н., Симаненков В.Т. и др. Коморбидная патология в клинической практике. Клинические рекомендации // Кардиоваскулярная терапия и профилактика. 2017. Т. 16 (6). С. 5–56 [Oganov R.G., Denisov I.N., Simanenkov V.T. i dr. Komorbidnaya patologiya v klinicheskoy praktike. Klinicheskiye rekomendatsii// Kardiovaskulyarnaya terapiya i profilaktika. 2017. T. 16 (6). S. 5–56 (in Russian)].
3. Вёрткин А.Л., Румянцев М.А., Скотников А.С. Коморбидность // Клиническая медицина. 2012. № 10. С. 4–11 [Vortkin A.L., Rumyantsev M.A., Skotnikov A.S. Komorbidnost’ // Klinicheskaya meditsina. 2012. № 10. S. 4–11 (in Russian)].
4. Linn B.S., Linn M.W., Gurel L. Cumulative illness rating scale // J. Amer. Geriatr. Soc. 1968. Vol. 16. P. 622–626.
5. Miller M.D., Towers A. Manual of Guidelines for Scoring the Cumulative Illness Rating Scale for Geriatrics (CIRS-G). Pittsburg, Pa: University of Pittsburgh; 1991.
6. De Groot V. How to measure comorbidity: a critical review of available methods // J. Clin.Epidemiol. 2003. Vol. 56 (3). P. 221–229.
7. Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatmentof coronary artery disease: a workshop consensus statement // Am. Heart J. 1991. Vol. 121. P. 1244–1263.
8. Dzau V., Elliott M.A., Henry R.B. et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease) // Circulation. 2006. Vol. 114 (25). P. 2850–2870.
9. Chrysant S.G. A new paradigm in the treatment of the cardiovascular disease continuum: focus on prevention // Hippokratia. 2011. Vol. 15 (1). P. 7–11.
10. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults // J. Am. Geriatr. Soc. 2012. Vol. 60 (4). P. 616–631.
11. Сычев Д.А., Данилина К.С., Отделенов В.А. Клинико-фармакологические подходы к решению проблемы полипрагмазии у пожилых пациентов в условиях многопрофильного стационара // Клиническая фармакология и терапия. 2013. Т. 22 (2). С. 1–6 [Sychev D.A., Danilina K.S., Otdelenov V.A. Kliniko-farmakologicheskiye podkhody k resheniyu problemy polipragmazii u pozhilykh patsiyentov v usloviyakh mnogoprofil’nogo statsionara // Klinicheskaya farmakologiya i terapiya. 2013. T. 22 (2). S. 1–6 (in Russian)].
12. Дамулин И.В., Екушева Е.В. Деменция вследствие поражения мелких церебральных сосудов: патогенез, клиника, лечение // Неврология, нейропсихиатрия, психосоматика. 2014. № 4. С. 94–100 [Damulin I.V., Yekusheva Ye.V. Dementsiya vsledstviye porazheniya melkikh tserebral’nykh sosudov: patogenez, klinika, lecheniye // Nevrologiya, neyropsikhiatriya, psikhosomatika. 2014. № 4. S. 94–100 (in Russian)].
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
